Nuvectra reports Q2 EPS (83c), consensus (91c)
Reports Q2 revenue $13.1M, consensus $11.68M. Scott Drees, CEO, said, "The second quarter represented another record quarter for our Algovita business, which benefited from new accounts, as well as from increased penetration in existing accounts. Our growth was further accelerated through the continued expansion of our U.S. commercial team, which now approximates 60 active territories. We look forward to further advancing our commercial momentum through 2018 and beginning to prepare for 2019." Mr. Drees continued, "With respect to Virtis, we have recently filed our response to FDA's requests, which we received late in the second quarter. FDA now has 180 days from our submission to review our response. Our focus remains on gaining U.S. approval as soon as possible, and we are working proactively with FDA to this end."